Diethylstilboestrol for the treatment of prostate cancer: past, present and future

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

(2013) Ruth E Langley et al.   LANCET ONCOLOGY

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer

(2013) Mark Stein et al.   MEDICAL SCIENCE MONITOR

A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol

(2011) J Shamash et al.   BRITISH JOURNAL OF CANCER

Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling

(2011) Arturo Molina et al.   JOURNAL OF UROLOGY

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial

(2011) Per Olov Hedlund et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Low-dose diethylstilbestrol for the treatment of advanced prostate cancer

(2011) Julia Clemons et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer

(2010) Jonathan Shamash et al.   CANCER

Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer

(2010) A J Armstrong et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer

(2009) C. Serrate et al.   ANNALS OF ONCOLOGY

The Mechanism of Action of Estrogen in Castration-Resistant Prostate Cancer: Clues From Hormone Levels

(2009) Rahul Aggarwal et al.   Clinical Genitourinary Cancer

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer

(2008) Ruth E. Langley et al.   BJU INTERNATIONAL

Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy

(2008) R A Cox et al.   BRITISH JOURNAL OF CANCER

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer

(2008) J Shamash et al.   BRITISH JOURNAL OF CANCER

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

(2008) Per Olov Hedlund et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

(2008) Celestia S Higano   Nature clinical practice. Urology

Diagnosis and treatment of prostate cancer: summary of NICE guidance

(2008) John Graham et al.   BMJ-British Medical Journal